Lyell Will Seek To Improve On Existing CAR-Ts Via Merger With ImmPACT

Lyell believes ImmPACT’s dual CD19/20-targeted CAR-T could offer better response rates than Yescarta or Breyanzi and will focus on IMPT-314 while terminating much of its own pipeline.

(Shutterstock)

Despite significant fundraising results to date, Lyell Immunopharma has been stuck in neutral with its own cancer cell therapy efforts, and the firm revealed on 24 October that it is merging with privately held ImmPACT Bio, bringing that company’s Phase I chimeric antigen receptor T-cell (CAR-T) therapy candidate into its pipeline and shuttering some of its own existing R&D candidates. Among other changes, Lyell is ceasing its efforts in tumor-infiltrating lymphocyte (TIL) therapies.

Key Takeaways
  • Lyell will pay $30m up front plus a sizeable equity stake to acquire ImmPACT Bio and its Phase I dual anti-CD19/20 CAR-T therapy for B-cell non-Hodgkin lymphoma.

On a same-day investor call, Lyell CEO Lynn Sealy said ImmPACT’s lead candidate, the dual-targeting CD19/20-directed CAR-T candidate IMPT-314, may...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Cell Therapies

More from Therapy Areas

Sumitomo Parkinson’s Filing A Pivotal Moment For Japan’s iPSC Ambitions

 
• By 

Sumitomo Pharma's iPSC therapy for Parkinson's has been filed for approval in Japan after showing safety and efficacy in a Phase I/II trial and may become one of the first such therapies to reach the market in the country, which has invested heavily in the modality.

HHS mRNA Vaccine Wind-Down Has Limited Impact (And One Contract Isn’t Even mRNA)

 

The news will have a big impact on pandemic preparedness but less immediate financial impact. Tiba Biotech was even “caught off guard” by its inclusion in the department’s culling of mRNA vaccine projects under BARDA, as its project was neither a vaccine nor mRNA-based.

Direct-To-Consumer And Lower Prices Key To Novo Nordisk’s Wegovy Fightback

 

The company’s incoming CEO Mike Doustdar has promised greater agility, competitiveness and execution, but investors are yet to be convinced.